Xilio Therapeutics, Inc.

Contributing Author

Recent Articles by Xilio Therapeutics, Inc.

Jun-02	Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering XLO -34.57% GlobeNewswire
Jun-02	Xilio Therapeutics Announces Proposed Public Offering XLO -34.57% GlobeNewswire
May-31	Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer XLO GlobeNewswire
May-08	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results XLO GlobeNewswire
May-02	Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) XLO GlobeNewswire